Stay updated with breaking news from Hpcapture. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Global nickel output to grow by 6.8% in 2021, backed by Indonesia and the Philippines mining-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mining-technology.com Daily Mail and Mail on Sunday newspapers.
Blockchain: Regulatory Trends identified by GlobalData offshore-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from offshore-technology.com Daily Mail and Mail on Sunday newspapers.
Benchmark Industrial buys Donby Shippers Supply packaging-gateway.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from packaging-gateway.com Daily Mail and Mail on Sunday newspapers.
Russia abandons tax incentives for extra viscous oil fields while still favouring Arctic developments By GlobalData Energy 07 May 2021 (Last Updated May 7th, 2021 10:00) Historically, all the upstream acreage in Russia had been granted in the form of mining concession agreements to Russian companies, except acreage granted under the three PSAs signed between 1994 and 1995. Share Article Historically, all the upstream acreage in Russia had been granted in the form of mining concession agreements to Russian companies, except acreage granted under the three PSAs signed between 1994 and 1995. A signature bonus, excess flaring and annual rental fees are payable for concession licenses, which in most cases are awarded through open auctions. Export duty is payable with oil rates depending on the Urals price and a 30% marginal rate whilst the rate for gas is set at 30% (excluding LNG). Mineral Extr ....
Todos Medical starts trial of protease inhibitor to treat Covid-19 20 Apr 2021 (Last Updated April 20th, 2021 10:48) Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients. Share Article Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients. The 77-patient, randomised, double blind, placebo-controlled trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel. Todos Medical is developing the therapeutic agent Tollovir through a joint venture with NLC Pharma. ....